Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 19(8): e0309301, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39172877

RESUMO

Tendinopathy is a common age-related disease which causes significant morbidity for both human athletes and performance horses. In the latter, the superficial digital flexor tendon is an excellent model for human tendinopathies because it is a functional homologue of the human Achilles tendon and a primary site of injuries with strong similarities to the human disease. Corticosteroids have been previously used clinically to treat tendinopathic inflammation, but they upregulate the p53-p21 axis with concomitant reductions in cell proliferation and collagen synthesis in human tenocytes. This phenotype is consistent with the induction of cellular senescence in vitro and in vivo and probably represents an important clinical barrier to their effective use. Because of the many differences in senescence mechanisms between species, this study aimed to evaluate these mechanisms after corticosteroid treatment in equine tenocytes. Exposure to clinically reflective levels of dexamethasone for 48 hours drove equine tenocytes into steroid induced senescence (SIS). This was characterised by permanent growth arrest and upregulation of p53, the cyclin dependent kinase inhibitors p21waf and p16ink4a as well as the matrix degrading enzymes MMP1, MMP2 and MMP13. SIS also induced a distinctive equine senescence associated secretory phenotype (eSASP) characterised by enhanced secretion of IL-8 and MCP-1. Preincubation with resveratrol or the potent SIRT1 activator SRT1720 prevented SIS in equine tenocytes, while treatment with the non-SIRT1 activating resveratrol analogue V29 was equally protective against SIS, consistent with a novel, as yet uncharacterised SIRT1-indendent mechanism which has relevance for the development of future preventative and therapeutic strategies.


Assuntos
Senescência Celular , Dexametasona , Sirtuína 1 , Tenócitos , Animais , Cavalos , Sirtuína 1/metabolismo , Senescência Celular/efeitos dos fármacos , Tenócitos/efeitos dos fármacos , Tenócitos/metabolismo , Dexametasona/farmacologia , Resveratrol/farmacologia , Proliferação de Células/efeitos dos fármacos , Proteína Supressora de Tumor p53/metabolismo , Tendinopatia/metabolismo , Tendinopatia/patologia , Tendinopatia/tratamento farmacológico , Células Cultivadas , Tendões/efeitos dos fármacos , Tendões/citologia , Tendões/metabolismo
2.
Stem Cell Rev Rep ; 20(4): 1040-1059, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38396222

RESUMO

Tissue fibrosis following tendon injury is a major clinical problem due to the increased risk of re-injury and limited treatment options; however, its mechanism remains unclear. Evidence suggests that insufficient resolution of inflammation contributes to fibrotic healing by disrupting tenocyte activity, with the NF-κB pathway being identified as a potential mediator. Equine embryonic stem cell (ESC) derived tenocytes may offer a potential cell-based therapy to improve tendon regeneration, but how they respond to an inflammatory environment is largely unknown. Our findings reveal for the first time that, unlike adult tenocytes, ESC-tenocytes are unaffected by IFN-γ, TNFα, and IL-1ß stimulation; producing minimal changes to tendon-associated gene expression and generating 3-D collagen gel constructs indistinguishable from unstimulated controls. Inflammatory pathway analysis found these inflammatory cytokines failed to activate NF-κB in the ESC-tenocytes. However, NF-κB could be activated to induce changes in gene expression following stimulation with NF-κB pharmaceutical activators. Transcriptomic analysis revealed differences between cytokine and NF-κB signalling components between adult and ESC-tenocytes, which may contribute to the mechanism by which ESC-tenocytes escape inflammatory stimuli. Further investigation of these molecular mechanisms will help guide novel therapies to reduce fibrosis and encourage superior tendon healing.


Assuntos
Citocinas , Células-Tronco Embrionárias , NF-kappa B , Tenócitos , Animais , Cavalos , Tenócitos/citologia , Tenócitos/metabolismo , Tenócitos/efeitos dos fármacos , Citocinas/metabolismo , NF-kappa B/metabolismo , Células-Tronco Embrionárias/citologia , Células-Tronco Embrionárias/metabolismo , Células-Tronco Embrionárias/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Inflamação/patologia , Inflamação/metabolismo , Células Cultivadas , Tendões/citologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA